Comprehensive medication guide to Jornay PM including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
Most commercial insurance plans that cover Jornay PM require prior authorization and may charge a specialty-tier copay of $75 to $150 per month, though the manufacturer savings card can reduce this to as low as $75.
Estimated Cash Pricing
Without insurance or discount cards, Jornay PM typically costs between $340 and $620 per month for a 30-capsule supply, depending on the strength and pharmacy.
Medfinder Findability Score
55/100
Summarize with AI
On this page
Jornay PM (methylphenidate hydrochloride) is an FDA-approved extended-release capsule used to treat Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 and older. What makes Jornay PM unique among ADHD stimulants is its evening dosing — patients take it between 6:30 PM and 9:30 PM, and the medication's delayed-release technology ensures that therapeutic levels are reached by the following morning and sustained throughout the day. This is especially helpful for patients who struggle with early-morning ADHD symptoms, such as difficulty getting ready for school or work.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Jornay PM contains methylphenidate, which works by blocking the reuptake of norepinephrine and dopamine into presynaptic neurons. This increases the concentration of these neurotransmitters in the brain, improving focus, attention, and impulse control. Jornay PM uses a proprietary delayed-release/extended-release (DR/ER) bead technology — less than 5% of the drug is absorbed in the first 10 hours after taking it in the evening, with peak therapeutic levels building by the next morning and lasting throughout the day.
20 mg extended-release capsules
40 mg extended-release capsules
60 mg extended-release capsules
80 mg extended-release capsules
100 mg extended-release capsules
Jornay PM earns a moderate findability score of 55. It is not on the FDA's official drug shortage list, and the manufacturer (Collegium Pharmaceutical) continues to produce it. However, because Jornay PM is a brand-only specialty medication with no generic equivalent, most retail pharmacies do not routinely stock it. Patients often need to call multiple pharmacies, try independent or specialty pharmacies, or request a special order. The broader ADHD stimulant shortage has also created additional competition for available supply. Using a tool like Medfinder can significantly speed up the search process.
Jornay PM is most commonly prescribed by psychiatrists, child and adolescent psychiatrists, and pediatricians who specialize in ADHD treatment. Primary care physicians and family medicine doctors may also prescribe it, particularly for adult patients. Because Jornay PM is a Schedule II controlled substance, all prescribers must hold a valid DEA registration. Some neurologists also prescribe it for patients with ADHD.
Yes. Jornay PM is classified as a Schedule II (CII) controlled substance by the DEA. This means it has a high potential for abuse and dependence. Prescriptions cannot be called in to pharmacies in most states — they must be sent electronically or provided as a written prescription. Refills are not allowed on Schedule II medications; a new prescription is required each time. The FDA's boxed warning notes that CNS stimulants including Jornay PM carry a risk of substance use disorder, including addiction, and that misuse can result in overdose and death.
Know what you need? Skip the search.
Concerta (methylphenidate ER)
A morning-dosed extended-release methylphenidate widely available as a generic at a much lower cost.
Vyvanse (lisdexamfetamine)
A long-acting prodrug stimulant now available as generic lisdexamfetamine, using an amphetamine-based mechanism.
Adderall XR (mixed amphetamine salts ER)
An extended-release amphetamine option, widely available as a generic with morning dosing.
Azstarys (serdexmethylphenidate/dexmethylphenidate)
A newer methylphenidate prodrug combination with morning dosing.
Prefer Jornay PM? We can find it.
MAO inhibitors
moderateDo not use Jornay PM with MAOIs or within 14 days of stopping one; risk of hypertensive crisis.
Halogenated anesthetics
moderateRisk of sudden blood pressure increase during surgery; inform your anesthesiologist.
Antihypertensive drugs
moderateMethylphenidate may reduce the effectiveness of blood pressure medications.
Anticoagulants (warfarin)
moderateMethylphenidate may increase warfarin levels; monitor closely.
Anticonvulsants (phenytoin, phenobarbital)
moderateMethylphenidate may increase their blood levels.
Tricyclic antidepressants
moderateMay increase TCA levels when taken with methylphenidate.
SSRIs and SNRIs
moderateIncreased risk of serotonin syndrome when combined.
Alcohol
moderateMay alter the release mechanism; avoid.
Jornay PM fills a unique niche in ADHD treatment as the only stimulant designed for evening dosing with next-morning onset. For patients who struggle with early-morning symptoms or can't tolerate the timing of traditional morning stimulants, it can be a game-changer. However, its brand-only status, higher cost, and limited pharmacy stocking mean that finding and affording Jornay PM takes extra effort. Use Medfinder to check real-time availability, explore the manufacturer savings card at jornaypm.com, and work with your prescriber to navigate insurance requirements. No generic is expected until 2032, so these strategies will remain important for the foreseeable future.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini